Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Sumitomo Dainippon Operating Profit Plummets 50% on Drug Price Cut, Generic Erosions
Sumitomo Dainippon Pharma suffered a plunge of over 50% in the first half of FY2018 as its Japan revenue was battered by the April 2018 drug price revision and relentless generic inroads, the company said on October 30. In April-September,…
To read the full story
Related Article
- Sumitomo Dainippon’s Sales Down 1.6% on Price Cuts, Generic Erosions
May 13, 2019
- Latuda Use Patent Suit Could Wrap Up in December: Sumitomo Dainippon Chief
May 14, 2018
- Sumitomo Dainippon’s Sales Hike 14.3% Buoyed by Latuda
May 14, 2018
- US Appeals Court Favors Sumitomo Dainippon in Latuda Substance Patent Suit
April 19, 2018
- Sumitomo Dainippon Sues 15 More Companies over Latuda Patent
February 27, 2018
- Sumitomo Dainippon Sues 2 Gx Makers over Latuda, Delays New 5-Year-Plan Announcement
February 15, 2018
BUSINESS
- Merck Biopharma Starts Japan PIII Trial of LH/FSH Combo
July 17, 2026
- Eisai’s Dayvigo Accepted for EMA Review
July 17, 2026
- AbbVie Files Maviret for Acute Hepatitis C
July 17, 2026
- FRONTEO, Santen Advance AI Drug Discovery Project to Second Phase
July 17, 2026
- Ferring’s Adstiladrin, Boehringer’s Jascayd Hit Market; Haizexin Due July 28
July 16, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…